{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T14:46:36Z","timestamp":1795013196425,"version":"4.9.1"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"am","delay-in-days":388,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.nucmedbio.2023.108368","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T02:43:02Z","timestamp":1689734582000},"page":"108368","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Preclinical studies of a PARP targeted, Meitner-Auger emitting, theranostic radiopharmaceutical for metastatic ovarian cancer"],"prefix":"10.1016","volume":"122-123","author":[{"given":"S.L.V.","family":"Hoffman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"Mixdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.R.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Makvandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Aluicio-Sarduy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.E.","family":"Barnhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Jeffery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.S.","family":"Patankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.W.","family":"Engle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.P.","family":"Bednarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.A.","family":"Ellison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.nucmedbio.2023.108368_bb0005","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.nucmedbio.2023.108368_bb0010","first-page":"23","article-title":"Cancer statistics, 2002","volume":"52","author":"Jemal","year":"2002","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.nucmedbio.2023.108368_bb0015","doi-asserted-by":"crossref","first-page":"viii36","DOI":"10.1093\/annonc\/mdx450","article-title":"Front-line therapy of advanced epithelial ovarian cancer: standard treatment","volume":"28","author":"Marth","year":"2017","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.nucmedbio.2023.108368_bb0020","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.7150\/thno.69424","article-title":"Platinum-based drugs for cancer therapy and anti-tumor strategies","volume":"12","author":"Zhang","year":"2022","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.nucmedbio.2023.108368_bb0025","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.critrevonc.2013.08.017","article-title":"Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer","volume":"89","author":"Colombo","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7353","key":"10.1016\/j.nucmedbio.2023.108368_bb0030","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"The Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.nucmedbio.2023.108368_bb0035","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejca.2016.03.005","article-title":"Homologous recombination deficiency and ovarian cancer","volume":"60","author":"Ledermann","year":"2016","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.nucmedbio.2023.108368_bb0040","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a016600","article-title":"Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins","volume":"7","author":"Prakash","year":"2015","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"355","key":"10.1016\/j.nucmedbio.2023.108368_bb0045","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"1979","author":"Lord","year":"2017","journal-title":"Science"},{"issue":"29","key":"10.1016\/j.nucmedbio.2023.108368_bb0050","first-page":"1","article-title":"Advances and perspectives of PARP inhibitors","volume":"8","author":"Yi","year":"2019","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.nucmedbio.2023.108368_bb0055","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nrclinonc.2014.163","article-title":"An update on PARP inhibitors\u2014moving to the adjuvant setting","volume":"12","author":"Sonnenblick","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.nucmedbio.2023.108368_bb0060","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/1471-0528.16411","article-title":"PARP inhibitors as maintenance therapy in newly diagnosed advanced ovarian cancer: a meta-analysis","volume":"128","author":"Lin","year":"2020","journal-title":"BJOG"},{"issue":"6486","key":"10.1016\/j.nucmedbio.2023.108368_bb0065","doi-asserted-by":"crossref","DOI":"10.1126\/science.aax6367","article-title":"Structural basis for allosteric PARP-1 retention on DNA breaks","volume":"368","author":"Zandarashvili","year":"2020","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.nucmedbio.2023.108368_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9072130","article-title":"Advancements in PARP1 targeted nuclear imaging and theranostic probes","volume":"9","author":"Ambur Sankaranarayanan","year":"2020","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.nucmedbio.2023.108368_bb0075","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/jamaoncol.2020.0334","article-title":"Positron emission tomography imaging of poly-(adenosine diphosphate-ribose) polymerase 1 expression in breast cancer: a nonrandomized clinical trial","volume":"6","author":"McDonald","year":"2020","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.nucmedbio.2023.108368_bb0080","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1148\/radiol.2016161929","article-title":"PET of poly (ADP-ribose) polymerase activity in cancer: preclinical assessment and first in-human studies","volume":"282","author":"Michel","year":"2017","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.nucmedbio.2023.108368_bb0085","article-title":"Preclinical and first-in-human-brain-cancer applications of [18F]poly (ADP-ribose) polymerase inhibitor PET\/MR","volume":"2","author":"Young","year":"2020","journal-title":"Neurooncol Adv"},{"issue":"6","key":"10.1016\/j.nucmedbio.2023.108368_bb0090","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2967\/jnumed.120.243287","article-title":"Molecular imaging: PARP-1 and beyond","volume":"62","author":"Puentes","year":"2021","journal-title":"J Nucl Med"},{"issue":"8","key":"10.1016\/j.nucmedbio.2023.108368_bb0095","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.146592","article-title":"In vivo visualization of PARP inhibitor pharmacodynamics","volume":"6","author":"McDonald","year":"2021","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.nucmedbio.2023.108368_bb0100","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s11307-015-0904-y","article-title":"Non-invasive PET imaging of PARP1 expression in glioblastoma models","volume":"18","author":"Carney","year":"2016","journal-title":"Mol Imaging Biol"},{"issue":"6","key":"10.1016\/j.nucmedbio.2023.108368_bb0105","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1158\/1078-0432.CCR-20-2766","article-title":"PARP inhibitors in cancer diagnosis and therapy","volume":"27","author":"Chan","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.nucmedbio.2023.108368_bb0110","doi-asserted-by":"crossref","first-page":"7290","DOI":"10.1021\/acs.orglett.1c02770","article-title":"Copper-mediated radiosynthesis of [18F]Rucaparib","volume":"23","author":"Chen","year":"2021","journal-title":"Org Lett"},{"issue":"11","key":"10.1016\/j.nucmedbio.2023.108368_bb0115","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1007\/s00259-022-05835-4","article-title":"Imaging PARP with [18F]rucaparib in pancreatic cancer models","volume":"49","author":"Chan","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"21","key":"10.1016\/j.nucmedbio.2023.108368_bb0120","doi-asserted-by":"crossref","first-page":"15690","DOI":"10.1021\/acs.jmedchem.1c00903","article-title":"DoE optimization empowers the automated preparation of Enantiomerically pure [18F]Talazoparib and its in vivo evaluation as a PARP radiotracer","volume":"64","author":"Bowden","year":"2021","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.nucmedbio.2023.108368_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9050565","article-title":"Radiosynthesis and evaluation of Talazoparib and its derivatives as PARP-1-targeting agents","volume":"9","author":"Zhou","year":"2021","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.nucmedbio.2023.108368_bb0130","doi-asserted-by":"crossref","first-page":"504","DOI":"10.2967\/jnumed.118.213223","article-title":"PET imaging of PARP expression using 18F-Olaparib","volume":"60","author":"Wilson","year":"2019","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.nucmedbio.2023.108368_bb0135","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41596-020-0295-7","article-title":"Manual and automated Cu-mediated radiosynthesis of the PARP inhibitor [18F]olaparib","volume":"15","author":"Guibbal","year":"2020","journal-title":"Nat Protoc"},{"issue":"8","key":"10.1016\/j.nucmedbio.2023.108368_bb0140","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2967\/jnumed.117.205054","article-title":"PARP-1-targeted radiotherapy in mouse models of glioblastoma","volume":"59","author":"Jannetti","year":"2018","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1016\/j.nucmedbio.2023.108368_bb0145","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1158\/1535-7163.MCT-18-0837","article-title":"Targeting PARP-1 with alpha-particles is potently cytotoxic to human neuroblastoma in preclinical models","volume":"18","author":"Makvandi","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.nucmedbio.2023.108368_bb0150","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1021\/acsptsci.0c00206","article-title":"PARP targeted alpha-particle therapy enhances response to PD-1 immune-checkpoint blockade in a syngeneic mouse model of glioblastoma","volume":"4","author":"Dabagian","year":"2021","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"1","key":"10.1016\/j.nucmedbio.2023.108368_bb0155","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/s42003-022-04209-8","article-title":"Pre-clinical investigation of astatine-211-parthanatine for high-risk neuroblastoma","volume":"5","author":"Makvandi","year":"2022","journal-title":"Commun Biol"},{"issue":"6","key":"10.1016\/j.nucmedbio.2023.108368_bb0160","doi-asserted-by":"crossref","first-page":"850","DOI":"10.2967\/jnumed.119.233965","article-title":"PARP-1-targeted auger emitters display high-LET cytotoxic properties in vitro but show limited therapeutic utility in solid tumor models of human neuroblastoma","volume":"61","author":"Lee","year":"2020","journal-title":"J Nucl Med"},{"issue":"9","key":"10.1016\/j.nucmedbio.2023.108368_bb0165","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1021\/acs.molpharmaceut.1c00323","article-title":"PARP-targeted Auger therapy in p53 mutant colon cancer xenograft mouse models","volume":"18","author":"Wilson","year":"2021","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1016\/j.nucmedbio.2023.108368_bb0170","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14010230","article-title":"Auger emitter conjugated PARP inhibitor for therapy in triple negative breast cancers: a comparative in-vitro study","volume":"14","author":"Sankaranarayanan","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"24","key":"10.1016\/j.nucmedbio.2023.108368_bb0175","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25246029","article-title":"PARP Theranostic Auger emitters are cytotoxic in BRCA mutant ovarian cancer and viable tumors from ovarian cancer patients enable ex-vivo screening of tumor response","volume":"25","author":"Riad","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.nucmedbio.2023.108368_bb0180","article-title":"Preclinical efficacy of a PARP-1 targeted Auger-emitting radionuclide in prostate cancer","volume":"24","author":"Sreekumar","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.nucmedbio.2023.108368_bb0185","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1158\/1078-0432.CCR-19-2440","article-title":"Targeted brain tumor radiotherapy using an auger emitter","volume":"26","author":"Pirovano","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.nucmedbio.2023.108368_bb0190","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13550-015-0123-1","article-title":"Radioiodinated PARP1 tracers for glioblastoma imaging","volume":"5","author":"Salinas","year":"2015","journal-title":"EJNMMI Res"},{"issue":"1","key":"10.1016\/j.nucmedbio.2023.108368_bb0195","doi-asserted-by":"crossref","DOI":"10.1186\/s41181-019-0075-2","article-title":"Auger electrons for cancer therapy \u2013 a review","volume":"4","author":"Ku","year":"2019","journal-title":"EJNMMI Radiopharm Chem"},{"key":"10.1016\/j.nucmedbio.2023.108368_bb0200","article-title":"A radioiodinated rucaparib analogue as an Auger electron emitter for cancer therapy","volume":"116\u2013117","author":"Destro","year":"2023","journal-title":"Nucl Med Biol"},{"issue":"5","key":"10.1016\/j.nucmedbio.2023.108368_bb0205","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40265-017-0716-2","article-title":"Rucaparib: first global approval","volume":"77","author":"Syed","year":"2017","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.nucmedbio.2023.108368_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.icrp.2008.10.001","article-title":"Nuclear decay data for dosimetric calculations. ICRP Publication 107","volume":"38","author":"Eckerman","year":"2008","journal-title":"Annals ICRP"},{"key":"10.1016\/j.nucmedbio.2023.108368_bb0215","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2174\/157016310793360657","article-title":"Targeting the nucleus: an overview of Auger-electron radionuclide therapy","volume":"7","author":"Cornelissen","year":"2010","journal-title":"Curr Drug Discov Technol"},{"key":"10.1016\/j.nucmedbio.2023.108368_bb0220","series-title":"Handbook of Radiopharmaceuticals","first-page":"441","article-title":"Radiobromine for imaging and therapy","author":"Rowland","year":"2005"},{"key":"10.1016\/j.nucmedbio.2023.108368_bb0225","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1385\/BTER:76:1:57","article-title":"Bromide kinetics and distribution in the rat. I","volume":"76","author":"Pavelka","year":"2000","journal-title":"Biol Trace Elem Res"},{"issue":"7","key":"10.1016\/j.nucmedbio.2023.108368_bb0230","doi-asserted-by":"crossref","DOI":"10.1007\/s002590050447","article-title":"Comparison of fluorine-18 and bromine-76 imaging in positron emission tomography","volume":"26","author":"Ribeiro","year":"1999","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2023.108368_bb0235","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1524\/ract.1983.34.12.41","article-title":"Radionuclides of bromine for use in biomedical studies","volume":"34","author":"Welch","year":"1983","journal-title":"Radiochim Acta"},{"key":"10.1016\/j.nucmedbio.2023.108368_bb0240","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.nucmedbio.2019.09.001","article-title":"Improved production of 76Br, 77Br and 80mBr via CoSe cyclotron targets and vertical dry distillation","volume":"80\u201381","author":"Ellison","year":"2020","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2023.108368_bb0245","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1021\/acs.joc.2c02420","article-title":"Copper-mediated radiobromination of (hetero)aryl boronic pinacol esters","volume":"88","author":"Mixdorf","year":"2023","journal-title":"J Organomet Chem"},{"issue":"5","key":"10.1016\/j.nucmedbio.2023.108368_bb0250","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1172\/JCI97992","article-title":"A PET imaging agent for evaluating PARP-1 expression in ovarian cancer","volume":"128","author":"Makvandi","year":"2018","journal-title":"J Clin Investig"},{"issue":"9","key":"10.1016\/j.nucmedbio.2023.108368_bb0255","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.2967\/jnumed.113.131037","article-title":"MIRD pamphlet no. 25: MIRDcell V2.0 software tool for dosimetric analysis of biologic response of multicellular populations","volume":"55","author":"Vaziri","year":"2014","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.nucmedbio.2023.108368_bb0260","first-page":"155","article-title":"Development and validation of RAPID: a patient-specific Monte Carlo three-dimensional internal dosimetry platform","volume":"33","author":"Besemer","year":"2018","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.nucmedbio.2023.108368_bb0265","series-title":"\u2018Tables and Graphs of Atomic Subshell and Relaxation Data Derived From the LLNL Evaluated Atomic Data Library (EADL), Z = 1--100\u2019, United States","author":"Perkins","year":"1991"},{"issue":"6","key":"10.1016\/j.nucmedbio.2023.108368_bb0270","first-page":"1023","article-title":"OLINDA\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine","volume":"46","author":"Stabin","year":"2005","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1016\/j.nucmedbio.2023.108368_bb0275","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.2967\/jnumed.118.225409","article-title":"Preclinical pharmacokinetics and dosimetry studies of 124I\/131I-CLR1404 for treatment of pediatric solid tumors in murine xenograft models","volume":"60","author":"Marsh","year":"2019","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.nucmedbio.2023.108368_bb0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0146-6453(03)00002-2","article-title":"Basic anatomical and physiological data for use in radiological protection: reference values: ICRP publication 89","volume":"32","author":"Valentin","year":"2002","journal-title":"Ann ICRP"},{"issue":"15","key":"10.1016\/j.nucmedbio.2023.108368_bb0285","doi-asserted-by":"crossref","first-page":"4516","DOI":"10.1158\/0008-5472.CAN-16-0416","article-title":"A radiotracer strategy to quantify PARP-1 expression in vivo provides a biomarker that can enable patient selection for PARP inhibitor therapy","volume":"76","author":"Makvandi","year":"2016","journal-title":"Cancer Res"},{"issue":"15","key":"10.1016\/j.nucmedbio.2023.108368_bb0290","doi-asserted-by":"crossref","first-page":"4516","DOI":"10.1158\/0008-5472.CAN-16-0416","article-title":"A radiotracer strategy to quantify PARP-1 expression in vivo provides a biomarker that can enable patient selection for PARP inhibitor therapy","volume":"76","author":"Makvandi","year":"2016","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.nucmedbio.2023.108368_bb0295","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.bmc.2014.01.019","article-title":"Synthesis, [18F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography","volume":"22","author":"Zhou","year":"2014","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.nucmedbio.2023.108368_bb0300","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.nucmedbio.2018.08.003","article-title":"Preliminary evaluation of a novel 18F-labeled PARP-1 ligand for PET imaging of PARP-1 expression in prostate cancer","volume":"66","author":"Zhou","year":"2018","journal-title":"Nucl Med Biol"},{"issue":"Supplement 3","key":"10.1016\/j.nucmedbio.2023.108368_bb0305","doi-asserted-by":"crossref","first-page":"23S","DOI":"10.2967\/jnumed.121.262751","article-title":"Normal-tissue tolerance to radiopharmaceutical therapies, the knowns and the unknowns","volume":"62","author":"Wahl","year":"2021","journal-title":"J Nucl Med"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805123000562?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805123000562?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T04:31:18Z","timestamp":1760848278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805123000562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":61,"alternative-id":["S0969805123000562"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2023.108368","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical studies of a PARP targeted, Meitner-Auger emitting, theranostic radiopharmaceutical for metastatic ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2023.108368","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108368"}}